Abstract
Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent. The currently used combination drug regimens produce cure rates that exceed 95%, given good patient adherence during the multiple months treatment period. However the recent surge in HIV infections and the synergy between HIV and TB as well as the emergence of resistance resulted in an unforeseen increase in the number of TB cases, including multi-drug resistant (MDR) and extensively-drug resistant (XDR) forms of TB. Consequently, there is an urgent need to develop novel, fast acting antituberculosis drugs with high potency that can provide treatment options for all forms of TB. It is well known that the current TB drugs exhibit differences in their in vivo activity profile and these differences are largely determined by their pharmacodynamics (PD), i.e. intrinsic antibacterial activity, biopharmaceutical properties such as solubility and permeability, and pharmacokinetic (PK) properties such as drug exposure, tissue distribution, and protein binding. An understanding of the relationships among these properties is considered key for a rational use of antituberculosis therapeutics. The current review provides a comprehensive summary of physicochemical/biopharmaceutical, PK, and PD properties of currently used antituberculosis drugs and novel agents under development. Also, a brief review of PK/PD parameters of current TB drugs is given and properties of a desirable TB drug target and drug molecule are outlined. The information provided herewith may be useful in the optimization of biopharmaceutical and PK/PD characteristics in the development of novel TB therapeutics and in the design of optimal treatment regimens.
Keywords: Tuberculosis, antituberculosis drug, pharmacokinetics, pharmacodynamics, biopharmaceutics, drugs development
Current Medicinal Chemistry
Title: Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs
Volume: 15 Issue: 8
Author(s): Nageshwar R. Budha, Richard E. Lee and Bernd Meibohm
Affiliation:
Keywords: Tuberculosis, antituberculosis drug, pharmacokinetics, pharmacodynamics, biopharmaceutics, drugs development
Abstract: Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent. The currently used combination drug regimens produce cure rates that exceed 95%, given good patient adherence during the multiple months treatment period. However the recent surge in HIV infections and the synergy between HIV and TB as well as the emergence of resistance resulted in an unforeseen increase in the number of TB cases, including multi-drug resistant (MDR) and extensively-drug resistant (XDR) forms of TB. Consequently, there is an urgent need to develop novel, fast acting antituberculosis drugs with high potency that can provide treatment options for all forms of TB. It is well known that the current TB drugs exhibit differences in their in vivo activity profile and these differences are largely determined by their pharmacodynamics (PD), i.e. intrinsic antibacterial activity, biopharmaceutical properties such as solubility and permeability, and pharmacokinetic (PK) properties such as drug exposure, tissue distribution, and protein binding. An understanding of the relationships among these properties is considered key for a rational use of antituberculosis therapeutics. The current review provides a comprehensive summary of physicochemical/biopharmaceutical, PK, and PD properties of currently used antituberculosis drugs and novel agents under development. Also, a brief review of PK/PD parameters of current TB drugs is given and properties of a desirable TB drug target and drug molecule are outlined. The information provided herewith may be useful in the optimization of biopharmaceutical and PK/PD characteristics in the development of novel TB therapeutics and in the design of optimal treatment regimens.
Export Options
About this article
Cite this article as:
Budha R. Nageshwar, Lee E. Richard and Meibohm Bernd, Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs, Current Medicinal Chemistry 2008; 15 (8) . https://dx.doi.org/10.2174/092986708783955509
DOI https://dx.doi.org/10.2174/092986708783955509 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile
Current Drug Safety Interleukin-4, Interleukin-13, Signal Transducer and Activator of Transcription Factor 6, and Allergic Asthma
Current Molecular Medicine 4-Mer Hyaluronan Oligosaccharides Stimulate Inflammation Response in Synovial Fibroblasts in Part via TAK-1 and in Part via p38-MAPK
Current Medicinal Chemistry QSAR Multi-Target in Drug Discovery: A Review
Current Computer-Aided Drug Design Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease
Current Pharmaceutical Design Antitubercular Properties of Substituted Hydroxycyclohexadienones
Letters in Drug Design & Discovery An Update of the Published Reports on Biologics Use for Psoriasis and the Reimbursement Status in Asia-Pacific Region
Current Rheumatology Reviews Pharmacological Control of Autophagy: Therapeutic Perspectives in Inflammatory Bowel Disease and Colorectal Cancer
Current Pharmaceutical Design Use of Genetically Modified Bacteria to Modulate Adaptive Immunity
Current Gene Therapy Sterol Biosynthesis Pathway as an Alternative for the Anti-Protozoan Parasite Chemotherapy
Current Medicinal Chemistry Inside the Pan-genome - Methods and Software Overview
Current Genomics Biologic Therapy in Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder
CNS & Neurological Disorders - Drug Targets 1,2,3-Triazole-Isoxazole Based Acetylcholinesterase Inhibitors: Synthesis, Biological Evaluation and Docking Study
Letters in Drug Design & Discovery Patent Selections
Recent Patents on Anti-Infective Drug Discovery Nucleotide Second Messenger Signaling as a Target for the Control of Bacterial Biofilm Formation
Current Topics in Medicinal Chemistry Organic Antifungal Drugs and Targets of Their Action
Current Topics in Medicinal Chemistry Meet the Editorial Board Member
Current Pharmaceutical Biotechnology Synthesis, Characterization and In Vitro Antiproliferative Effects of Novel 5-Amino Pyrazole Derivatives against Breast Cancer Cell Lines
Recent Patents on Anti-Cancer Drug Discovery Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies
Current Medicinal Chemistry